Clinical trial
An Open-label Study of NRP104 in Adults With Attention Deficit Hyperactivity…
NCT00337285 · New River Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00337285 |
|---|---|
| Title | An Open-label Study of NRP104 in Adults With Attention Deficit Hyperactivity Disorder (ADHD) |
| Official title | A Long-Term, Open-Label, and Single-Arm Study of NRP104 30 mg, 50 mg, or 70 mg Per Day in Adults With Attention Deficit Hyperactivity Disorder (ADHD) |
| Lead sponsor | New River Pharmaceuticals, Industry |
| Collaborators | Shire Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Attention Deficit Hyperactivity Disorder, Attention Deficit Disorders With Hyperactivity, Attention Deficit Hyperactivity Disorders |
| Intervention type | Drug |
| Interventions | Vyvanse (lisdexamfetamine dimesylate), NRP104 |
| Enrollment | 349 |
| Start date | Jul 1, 2006 |
| Primary completion | Nov 1, 2007 |
| Completion | Jun 1, 2008 |
| First posted | Jun 15, 2006 |
| Last update posted | Aug 20, 2012 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: